Deadline Date: April 27, 2026
The Ontario Brain Institute is now accepting applications to support early-stage entrepreneurs in Canada in building and commercializing innovative neurotechnology solutions.
The programme focuses on supporting early-stage entrepreneurs based in Canada by providing non-dilutive funding, training opportunities and workshops, mentorship, and structured milestone-based support to enable the commercialization of neurotechnology that improves how brain and brain-related disorders are understood, diagnosed, improved, or treated.
The programme awards up to five Canada-based early-stage entrepreneurs and provides $100,000 in non-dilutive funding along with access to training opportunities, workshops, and mentorship. Preference is given to applicants who have completed a post-graduate fellowship within the past five years. The funding is intended for project-related costs and may be partially used as a stipend, with allocation subject to approval and alignment with the project plan.
During the one-year programme, successful applicants are required to develop commercialization milestones and enter into a milestone-based agreement. Funding is released in three tranches, contingent upon achieving agreed milestones. Each awardee is assigned an industry-based mentor and works closely with a dedicated point of contact, while also being required to attend training and support programmes and participate in selected events organized by programme partners.
To be eligible, applicants must be early-stage entrepreneurs based in Canada and commit to working full-time on their venture during the programme. They must have an incorporated company or plans to incorporate a neurotechnology company in Canada. The company must focus on developing and commercializing technology based on scientific research that has a fundamental impact on understanding, diagnosing, improving, or treating brain and related disorders, including neurological, neuropsychiatric, or sensory diseases. The funding must be used specifically for the commercialization of neurotechnology such as devices, therapeutics, AI-based technologies, or software, with usage subject to review and approval.
For more information, visit OBI.
